Medicinal plant Combretum leprosum mart ameliorates motor, biochemical and molecular alterations in a Parkinson's disease model induced by MPTP

Journal of Ethnopharmacology

Volumn 185, Issue , 2016, Pages 68-76

  Moraes, Livia S ^a   Rohor, Bruna Z ^a   Areal, Lorena B ^a   Pereira, Evaldo V ^a   Santos, Alexandre M C ^a   Facundo, Valdir A ^c   Santos, Adair R S ^b   Pires, Rita G W ^a   Martins Silva, Cristina ^a  

^a FEDERAL UNIVERSITY OF ESPÍRITO SANTO   (Brazil)

^b FEDERAL UNIVERSITY OF SANTA CATARINA   (Brazil)

^c UNIVERSIDADE FEDERAL DE RONDÔNIA   (Brazil)

Author keywords

Combretum Leprosum; MPTP; Neuroinflammation; Parkinson's disease; Phytotherapeutic medicines

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; COMBRETUM LEPROSUM ETHANOLIC EXTRACT; DOPAMINE TRANSPORTER; NEUROPROTECTIVE AGENT; PLANT EXTRACT; TYROSINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG; 3,4 DIHYDROXYPHENYLACETIC ACID; DOPAMINE; HOMOVANILLIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COMBRETUM; COMBRETUM LEPROSUM; CONTROLLED STUDY; CORPUS STRIATUM; GENE EXPRESSION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LOCOMOTION; MALE; MOUSE; MUSCLE STRENGTH; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; ANIMAL; C57BL MOUSE; CHEMICALLY INDUCED; CHEMISTRY; DRUG EFFECTS; GENE EXPRESSION REGULATION; INTOXICATION; MEDICINAL PLANT; METABOLISM; PARKINSON DISEASE, SECONDARY; PHYSIOLOGY; POLYMERASE CHAIN REACTION;

3,4-DIHYDROXYPHENYLACETIC ACID; ANIMALS; COMBRETUM; DOPAMINE; GENE EXPRESSION REGULATION; HOMOVANILLIC ACID; MALE; MICE; MICE, INBRED C57BL; MPTP POISONING; PARKINSON DISEASE, SECONDARY; PLANT EXTRACTS; PLANTS, MEDICINAL; POLYMERASE CHAIN REACTION;

EID: 84961774975     PISSN: 03788741     EISSN: 18727573     Source Type: Journal    
DOI: 10.1016/j.jep.2016.03.041     Document Type: Article

References (65)

1. I.K. Adnyana, Y. Tezuka, A.H. Banskota, K.Q. Tran, and S. Kadota Three new triterpenes from the seeds of Combretum quadrangulare and their hepatoprotective activity J. Nat. Prod. 64 2001 360 363
2. S. Albrecht, and E. Buerger Potential neuroprotection mechanisms in PD: Focus on dopamine agonist pramipexole Curr. Med. Res. Opin. 25 2009 2977 2987
3. F. Blandini An update on the potential role of excitotoxicity in the pathogenesis of Parkinson's disease Funct. Neurol. 25 2010 65 71
4. F. Blandini, G. Nappi, C. Tassorelli, and E. Martignoni Functional changes of the basal ganglia circuitry in Parkinson's disease Prog. Neurobiol. 62 2000 63 88
5. S.M. Burke, E. van de Giessen, M. de Win, T. Schilt, M. van Herk, W. van den Brink, and J. Booij Serotonin and dopamine transporters in relation to neuropsychological functioning, personality traits and mood in young adult healthy subjects Psychol. Med. 41 2011 419 429
6. L. Chagniel, C. Robitaille, C. Lacharite-Mueller, G. Bureau, and M. Cyr Partial dopamine depletion in MPTP-treated mice differentially altered motor skill learning and action control Behav. Brain Res. 228 2012 9 15
7. P.C. Chen, M.R. Vargas, A.K. Pani, R.J. Smeyne, D.A. Johnson, Y.W. Kan, and J.A. Johnson Nrf2-mediated neuroprotection in the MPTP mouse model of Parkinson's disease: Critical role for the astrocyte Proc. Natl. Acad. Sci. USA 106 2009 2933 2938
8. L.G. Chia, D.R. Ni, F.C. Cheng, Y.P. Ho, and J.S. Kuo Intrastriatal injection of 5,7-dihydroxytryptamine decreased 5-HT levels in the striatum and suppressed locomotor activity in C57BL/6 mice Neurochem Res. 24 1999 719 722
9. L.G. Chia, D.R. Ni, L.J. Cheng, J.S. Kuo, F.C. Cheng, and G. Dryhurst Effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and 5,7-dihydroxytryptamine on the locomotor activity and striatal amines in C57BL/6 mice Neurosci. Lett. 218 1996 67 71
10. A. Cirla, and J. Mann Combretastatins: From natural products to drug discovery Nat. Prod. Rep. 20 2003 558 564
11. V.A. Colotla, E. Flores, A. Oscos, A. Meneses, and R. Tapia Effects of MPTP on locomotor activity in mice Neurotoxicol. Teratol. 12 1990 405 407
12. W. Dauer, and S. Przedborski Parkinson's disease: Mechanisms and models Neuron 39 2003 889 909
13. L.M. de Lau, and M.M. Breteler Epidemiology of Parkinson's disease Lancet Neurol. 5 2006 525 535
14. I.D. Della-Pace, L.M. Rambo, L.R. Ribeiro, A.L. Saraiva, S.M. de Oliveira, C.R. Silva, J.G. Villarinho, M.F. Rossato, J. Ferreira, L.M. de Carvalho, F. de Oliveira Lima, A.F. Furian, M.S. Oliveria, A.R. Santos, V.A. Facundo, M.R. Fighera, and L.F. Royes Triterpene 3beta, 6beta, 16beta trihidroxilup-20(29)-ene protects against excitability and oxidative damage induced by pentylenetetrazol: The role of Na(+),K(+)-ATPase activity Neuropharmacology 67 2013 455 464
15. E.R. Dorsey, R. Constantinescu, J.P. Thompson, K.M. Biglan, R.G. Holloway, K. Kieburtz, F.J. Marshall, B.M. Ravina, G. Schifitto, A. Siderowf, and C.M. Tanner Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030 Neurology 68 2007 384 386
16. A. Floel, G. Garraux, B. Xu, C. Breitenstein, S. Knecht, P. Herscovitch, and L.G. Cohen Levodopa increases memory encoding and dopamine release in the striatum in the elderly Neurobiol. Aging 29 2008 267 279
17. P.B. Forgacs, and I. Bodis-Wollner Nicotinic receptors and cognition in Parkinson's Disease: The importance of neuronal synchrony J. Neural Transm. 111 2004 1317 1331
18. S.C. Fowler, T.J. Zarcone, E. Vorontsova, and R. Chen Motor and associative deficits in D2 dopamine receptor knockout mice Int. J. Dev. Neurosci. 20 2002 309 321
19. S.H. Fox, and J.M. Brotchie 5-HT2C receptor binding is increased in the substantia nigra pars reticulata in Parkinson's disease Mov. Disord. 15 2000 1064 1069
20. S.D. Glick, and R.G. Marsanico Comparative time-dependent changes in sensitivity to locomotor effects of d-amphetamine in mice with caudate, hippocampal or frontal cortical lesions Arch. Int. Pharm. Ther. 209 1974 80 85
21. D.G. Grahame-Smith Studies in vivo on the relationship between brain tryptophan, brain 5-HT synthesis and hyperactivity in rats treated with a monoamine oxidase inhibitor and l-tryptophan J. Neurochem. 18 1971 1053 1066
22. D.M. Helmeste, and P. Seeman Amphetamine-induced hypolocomotion in mice with more brain D2 dopamine receptors Psychiatry Res. 7 1982 351 359
23. C.D. Horinouchi, D.A. Mendes, S. Soley Bda, E.F. Pietrovski, V.A. Facundo, A.R. Santos, D.A. Cabrini, and M.F. Otuki Combretum leprosum Mart. (Combretaceae): Potential as an antiproliferative and anti-inflammatory agent J. Ethnopharmacol. 145 2013 311 319
24. J.A. Hutter-Saunders, H.E. Gendelman, and R.L. Mosley Murine motor and behavior functional evaluations for acute 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) intoxication J. Neuroimmune Pharm. 7 2012 279 288
25. M.W. Jakowec, K. Nixon, E. Hogg, T. McNeill, and G.M. Petzinger Tyrosine hydroxylase and dopamine transporter expression following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurodegeneration of the mouse nigrostriatal pathway J. Neurosci. Res. 76 2004 539 550
26. T.M. Jay Dopamine: A potential substrate for synaptic plasticity and memory mechanisms Prog. Neurobiol. 69 2003 375 390
27. P. Klivenyi, and L. Vecsei Novel therapeutic strategies in Parkinson's disease Eur. J. Clin. Pharm. 66 2010 119 125
28. E.A. Kozina, G.R. Khakimova, V.G. Khaindrava, V.G. Kucheryanu, N.E. Vorobyeva, A.N. Krasnov, S.G. Georgieva, L. Kerkerian-Le Goff, and M.V. Ugrumov Tyrosine hydroxylase expression and activity in nigrostriatal dopaminergic neurons of MPTP-treated mice at the presymptomatic and symptomatic stages of parkinsonism J. Neurol. Sci. 340 2014 198 207
29. D.M. Kuhn, D.M. Francescutti-Verbeem, and D.M. Thomas Dopamine disposition in the presynaptic process regulates the severity of methamphetamine-induced neurotoxicity Ann. N Y Acad. Sci. 1139 2008 118 126
30. R. Kurosaki, Y. Muramatsu, H. Kato, and T. Araki Biochemical, behavioral and immunohistochemical alterations in MPTP-treated mouse model of Parkinson's disease Pharm. Biochem. Behav. 78 2004 143 153
31. D. Liebetanz, P.C. Baier, W. Paulus, K. Meuer, M. Bahr, and J.H. Weishaupt A highly sensitive automated complex running wheel test to detect latent motor deficits in the mouse MPTP model of Parkinson's disease Exp. Neurol. 205 2007 207 213
32. D.T. Longhi-Balbinot, D. Lanznaster, C.H. Baggio, M.D. Silva, C.H. Cabrera, V.A. Facundo, and A.R. Santos Anti-inflammatory effect of triterpene 3beta, 6beta, 16beta-trihydroxylup-20(29)-ene obtained from Combretum leprosum Mart & Eich in mice J. Ethnopharmacol. 142 2012 59 64
33. D.T. Longhi-Balbinot, E.F. Pietrovski, V.M. Gadotti, D.F. Martins, V.A. Facundo, and A.R. Santos Spinal antinociception evoked by the triterpene 3beta, 6beta, 16beta-trihydroxylup-20(29)-ene in mice: Evidence for the involvement of the glutamatergic system via NMDA and metabotropic glutamate receptors Eur. J. Pharmacol. 623 2009 30 36
34. L.S. Lopes, R.B. Marques, S.S. Pereira, M.C. Ayres, M.H. Chaves, A.J. Cavalheiro, G.M. Vieira Junior, and F.R. Almeida Antinociceptive effect on mice of the hydroalcoholic fraction and (-) epicatechin obtained from Combretum leprosum Mart & Eich Braz. J. Med. Biol. Res. 43 2010 1184 1192
35. D.W. Luchtman, D. Shao, and C. Song Behavior, neurotransmitters and inflammation in three regimens of the MPTP mouse model of Parkinson's disease Physiol. Behav. 98 2009 130 138
36. N.D. Martini, D.R. Katerere, and J.N. Eloff Biological activity of five antibacterial flavonoids from Combretum erythrophyllum (Combretaceae) J. Ethnopharmacol. 93 2004 207 212
37. C. Martins-Silva, X. De Jaeger, M.S. Guzman, R.D. Lima, M.S. Santos, C. Kushmerick, M.V. Gomez, M.G. Caron, M.A. Prado, and V.F. Prado Novel strains of mice deficient for the vesicular acetylcholine transporter: Insights on transcriptional regulation and control of locomotor behavior PLoS One 6 2011 e17611
38. K. Matsuura, H. Kabuto, H. Makino, and N. Ogawa Pole test is a useful method for evaluating the mouse movement disorder caused by striatal dopamine depletion J. Neurosci. Methods 73 1997 45 48
39. L.J. McGaw, T. Rabe, S.G. Sparg, A.K. Jager, J.N. Eloff, and J. van Staden An investigation on the biological activity of Combretum species J. Ethnopharmacol. 75 2001 45 50
40. G.W. Miller, J.K. Staley, C.J. Heilman, J.T. Perez, D.C. Mash, D.B. Rye, and A.I. Levey Immunochemical analysis of dopamine transporter protein in Parkinson's disease Ann. Neurol. 41 1997 530 539
41. K. Modigh Central and peripheral effects of 5-hydroxytryptophan on motor activity in mice Psychopharmacologia 23 1972 48 54
42. N.H. Nam Combretastatin A-4 analogues as antimitotic antitumor agents Curr. Med. Chem. 10 2003 1697 1722
43. P.H. Nunes, P.M. Cavalcanti, S.M. Galvao, and M.C. Martins Antiulcerogenic activity of Combretum leprosum Pharmazie 64 2009 58 62
44. N. Ogawa, Y. Hirose, S. Ohara, T. Ono, and Y. Watanabe A simple quantitative bradykinesia test in MPTP-treated mice Res. Commun. Chem. Pathol. Pharmacol. 50 1985 435 441
45. O.A. Olajide, J.M. Makinde, and D.T. Okpako Evaluation of the anti-inflammatory property of the extract of Combretum micranthum G. Don (Combretaceae) Inflammopharmacology 11 2003 293 298
46. C.W. Olanow Rationale for considering that propargylamines might be neuroprotective in Parkinson's disease Neurology 66 2006 S69 S79
47. E. Petroske, G.E. Meredith, S. Callen, S. Totterdell, and Y.S. Lau Mouse model of Parkinsonism: A comparison between subacute MPTP and chronic MPTP/probenecid treatment Neuroscience 106 2001 589 601
48. G. Pezzoli, and M. Zini Levodopa in Parkinson's disease: From the past to the future Expert Opin. Pharm. 11 2010 627 635
49. E.F. Pietrovski, K.A. Rosa, V.A. Facundo, K. Rios, M.C. Marques, and A.R. Santos Antinociceptive properties of the ethanolic extract and of the triterpene 3beta,6beta,16beta-trihidroxilup-20(29)-ene obtained from the flowers of Combretum leprosum in mice Pharmacol. Biochem. Behav. 83 2006 90 99
50. W. Poewe The need for neuroprotective therapies in Parkinson's disease: A clinical perspective Neurology 66 2006 S2 S9
51. E. Rousselet, C. Joubert, J. Callebert, K. Parain, L. Tremblay, G. Orieux, J.M. Launay, C. Cohen-Salmon, and E.C. Hirsch Behavioral changes are not directly related to striatal monoamine levels, number of nigral neurons, or dose of parkinsonian toxin MPTP in mice Neurobiol. Dis. 14 2003 218 228
52. K. Sango, M.P. McDonald, J.N. Crawley, M.L. Mack, C.J. Tifft, E. Skop, C.M. Starr, A. Hoffmann, K. Sandhoff, K. Suzuki, and R.L. Proia Mice lacking both subunits of lysosomal beta-hexosaminidase display gangliosidosis and mucopolysaccharidosis Nat. Genet. 14 1996 348 352
53. A.H. Schapira Etiology of Parkinson's disease Neurology 66 2006 S10 S23
54. M. Sedelis, K. Hofele, G.W. Auburger, S. Morgan, J.P. Huston, and R.K. Schwarting MPTP susceptibility in the mouse: Behavioral, neurochemical, and histological analysis of gender and strain differences Behav. Genet. 30 2000 171 182
55. R.J. Smeyne, and V. Jackson-Lewis The MPTP model of Parkinson's disease Brain Res. Mol. Brain Res. 134 2005 57 66
56. T.D. Sotnikova, J.M. Beaulieu, L.S. Barak, W.C. Wetsel, M.G. Caron, and R.R. Gainetdinov Dopamine-independent locomotor actions of amphetamines in a novel acute mouse model of Parkinson disease PLoS Biol. 3 2005 e271
57. S. Stayte, and B. Vissel Advances in non-dopaminergic treatments for Parkinson's disease Front. Neurosci. 8 2014 113
58. F. Stocchi The therapeutic concept of continuous dopaminergic stimulation (CDS) in the treatment of Parkinson's disease Parkinsonism Relat. Disord. 15 Suppl. 3 2009 S68 S71
59. E. Sundstrom, J. Luthman, M. Goldstein, and G. Jonsson Time course of MPTP-induced degeneration of the nigrostriatal dopamine system in C57 BL/6 mice Brain Res. Bull. 21 1988 257 263
60. J. Szyndler, P. Maciejak, D. Turzynska, A. Sobolewska, A. Bidzinski, and A. Plaznik Time course of changes in the concentrations of monoamines in the brain structures of pentylenetetrazole-kindled rats J. Neural Transm. 117 2010 707 718
61. F. Thibaut, B.A. Faucheux, J. Marquez, J. Villares, J.F. Menard, Y. Agid, and E.C. Hirsch Regional distribution of monoamine vesicular uptake sites in the mesencephalon of control subjects and patients with Parkinson's disease: A postmortem study using tritiated tetrabenazine Brain Res. 692 1995 233 243
62. Y. Watanabe, H. Kato, and T. Araki Protective action of neuronal nitric oxide synthase inhibitor in the MPTP mouse model of Parkinson's disease Metab. Brain Dis. 23 2008 51 69
63. B.D. West, P.J. Shughrue, A.E. Vanko, R.W. Ransom, and G.G. Kinney Amphetamine-induced locomotor activity is reduced in mice following MPTP treatment but not following selegiline/MPTP treatment Pharmacol. Biochem. Behav. 84 2006 158 161
64. G.L. Willis, and G.A. Donnan Histochemical, biochemical and behavioural consequences of MPTP treatment in C-57 black mice Brain Res. 402 1987 269 274
65. F.M. Zhou, C. Wilson, and J.A. Dani Muscarinic and nicotinic cholinergic mechanisms in the mesostriatal dopamine systems Neuroscientist 9 2003 23 36